Frans BOTS

En résumé

Entreprises

• Consultant Indépendant - Global Biotech & Pharma Executive

  2014 - maintenant -Dynamic and visionary business leader with significant experience and expertise in Strategy, Market Access, Sales & Marketing, New Business Development, Regulatory,Medical & Clinical Affairs, Registration, Pricing & Reimbursement including 15 years as Multi-Country CEO
  
  -Creativity,Innovation
  -Exceptional results in highly competitive markets
  -Double-digit growth year after year
  
  Hands-on experience in
  Business development,sales, product & marketing management,marketing plans,marketing research,local and global marketing strategy, positioning,patient profiles,market development,market access,product (pre)launch and relaunch,product life cycle management,coaching,sales force effectiveness,people management,start-ups, project management, key opinion leader development, clinical research, clinical trials, medical plans, pricing & reimbursement, lobbying health care and reimbursement authorities, building business units and a company subsidiary from scratch
  
  
  Selected projects
  
  -mAbs
  -Market Access
  -Global growth of OncoDNA
  -Strategy to acquire a company for UK Pharma(£100M)
  -Strategy to raise $ 25M for US Biotech
  -Fundraising($15M) and Growth of LuTran Inc,USA(HIV,ebola virus,Alzheimer's)
  -Fundraising($160M) for LuTran, project to improve 100 compounds from top 10 pharma companies pipelines
  -Fundraising($22M) for Met Syn Lysine Ltd,Israel(diabetes, obesity, RA, oncology,orphan diseases)
  -Out-licensing Pro-Drug technology for peptides and proteins
  -Fundraising Biotech Canada
  - Selling of European PhytoCompany
  -MedTech, USA Fundraising $19M (Instant and long term back pain relief).An earlier project of the company was acquired for $1,1B
  -Int Biotech, out-licensing multitarget cancer immunotherapy (10 protein targets) and anti-TNF molecule with $ multibillion revenue forecasts

• Adventura Capital - Mentor & Consultant

  2014 - maintenant Adventura Capital- Linking International Capital to the Spanish Technology Industry
  The Mentor is a successful entrepreneur who uses his know-how and extensive network to help these companies.

• Pierre Fabre - Director Oncology & Hematology Benelux

  Castres 2010 - 2012 Result
  -Proposing a collaboration opportunity for a biotech therapy (gene therapy) with major future sales potential to corporate HQ
  -Proposing a collaboration opportunity for monoclonal antibodies to corporate HQ

• Pierre Fabre - Managing Director Pierre Fabre Médicament Benelux

  Castres 1995 - 2010 Building from scratch, growing, managing and leading a pharmaceutical company, specialized in drugs for the treatment of cancer, hematological malignancies and in orphan drugs
  Setting-up of administrative, regulatory affairs, sales & clinical research teams
  Initiating and supervising clinical studies and investigator driven trials to support the marketing of key drugs
  -P&L responsibility
  -Major hands on involvement in Price & Reimbursement and Market Access
  Benelux Price & Reimbursement, Market Access experience includes an orphan drug for pediatric patients and adults and 4 cytostatic drugs for lung, breast and bladder cancer
  Communicating key issues related to government affairs and P&R policy to internal and external stakeholders
  Developing recommendations and strategic advice to international company HQ regarding Price & Reimbursement Strategy
  Oversee the creation of robust Price & Reimbursement dossiers in Benelux
  Critical revisions and significant contributions to Price and Reimbursement dossiers
  Lobbying members of Reimbursement Committee
  Lobbying Key Opinion Leaders and Patient Organizations to obtain support for reimbursements
  Translating Strategy into operational goals and objectives
  Developing marketing & medical plans and long range business plans
  Budgeting, forecasting
  Strategic planning, marketing strategy,(pre) launch, post-launch, life cycle management
  Sales Force effectiveness, sales force action plans to correct deviations from budget
  Medical & Regulatory Affairs, Pharmacovigilance
  P & L responsibility
  Cost Control
  Key Opinion Leader development
  Transferring Adverse Drug Reactions (Pharmacovigilance)
  Contract/ price negotiating
  Developing and implementing a highly effective anti-generic strategy
  Participating in cross functional & multinational teams concerned with new product launches
  Evaluating a number of own and in- licensing drugs/treatments ( cancer, cardiovascular, urology, gynecology, gene therapy)
  Distribution logistics
  Result
  -Navelbine Netherlands: creative strategy to obtain reimbursement when reimbursement
  was impossible according to official regulation
  -Launch Navelbine Belgium: highest market share and sales per capita of all affiliates worldwide
  -Busilvex Benelux successful launch and market penetration in leukemia, lymphoma
  -Creation of the most successful anti-generic strategy of all affiliates worldwide with 90% of
  volume still protected several years after generic market entry
  -Excellent results with limited resources in a highly competitive market dominated by Big Pharma

• American Cyanamid-Lederle - Marketing Director

  1993 - 1995 Developing and implementing yearly business and marketing plan (Novantrone, Ledervorin, Methotrexate)
  Relaunch Ledervorin in colorectal cancer: new marketing and position strategy, KOL management, product presentations oncology staff meetings
  Result
  -Doubling flat product sales of 5 MM EUR to 11 Million EUR in
  2 years
  -Belgian oncology division becomes the most profitable division of Cyanamid Benelux and also the number one Cyanamid oncology division worldwide (highest market share and sales per capita

• Lederle - Project Manager

  1990 - 1992 Start- up of this innovative new treatment approach for cancer in university centers
  Furthermore responsible for all pre marketing activities, as well as the implementation
  and follow-up of clinical research (Phase II and III)
  Photodynamic therapy is a unique treatment method for cancer, which combines a light-
  sensitive drug with laser therapy

• Lederle - Business Unit Manager

  1988 - 1989 Responsible for starting up a new Business Unit, all marketing and sales
  Activities and clinical research (Phase IV)
  International test market: Belgium
  Result
  -Excellent
  -Other affiliates also started a dental business unit following the results in Belgium (UK, Portugal, Spain).
  End year evaluation
  Strong points: good communication, highly developed strategic thinking, excellent leader
  and motivator

• Lederle - Product Manager Infectious Diseases & Oncology

  1986 - 1987 Sales € 6.5 Million (sales versus budget:135%)

• Lederle - Product Manager

  1984 - 1985 Result
  -Highest market share worldwide (9 %)
  -Developing locally a very creative and innovative scientific relaunch marketing and positioning strategy that was implemented thereafter by HQ as a global marketing strategy generating $ 700 Million of additional cumulative revenue worldwide

• Lederle - National Sales Director

  1982 - 1983 Result
  Sales 1st year : 1.6 Million EUR ,

Formations

• Gltt (Rhode Saint Genese)

  Rhode Saint Genese 2014 - 2018 Italian(2 yrs),Chinese(1 year),Japanese (2 yrs),Russian(3 yrs))

• University Of Leuven (KU Leuven) (Leuven (Belgium))

  Leuven (Belgium) 1986 - 1987 Postgraduate Business Administration
  
  

• MD Anderson Cancer Center Texas USA (Houston)

  Houston 1985 - 1985 Preceptorship in Oncology

• Leidse Onderwijsinstellingen (Leiderdorp)

  Leiderdorp 1980 - 1981 Primary Medical Knowledge

• COCMA (Utrecht)

  Utrecht 1975 - 1978 Bachelors French Language

Réseau

• Antoine DURAL

• Aurélie ROPIOT

• Aurielle DU

• Corinne HANON

• Farghali MBAREK

• Hanan EL YOUSFI

• Jeoffrey GONZALES

• Veronique WIDEMANN

• Yacouba ZANGO